TFAP2A and gastric cancer: Similarly, EGCG reduces the expression of MDR1 and P-gp through the TFAP2A/VEGF pathway, thus restoring the sensitivity of gastric cancer cells to 5-fluorouracil (5-FU) (Tang et al., 2017).